Piperazine compounds

Abstract

A compound selected from those of formula: ##STR1## wherein: A--B, n, D and E are as defined in the specification, their racemic mixtures, and their optical isomers, and also the physiologically tolerable salts thereof with appropriate acids. The products of the invention may be used therapeutically.

We claim: 
     
       1. A compound selected from the group consisting of: 1- 2-(benzocyclobutan-1-yl)ethyl!-4-(2,3-dihydro-5-methoxybenzofuran-6-yl)piperazine,   4-(2,3-dihydrobenzo-1,4-dioxin-6-yl)-1-(indan-2-ylmethyl)piperazine, and   1-(indan-2-ylmethyl)-4-(2,3-dihydro-5-methoxybenzofuran-6-yl)piperazine,   and pharmaceutically-acceptable acid addition salts thereof.   
     
     
       2. A compound which is: 1- 2-(benzocyclobutan-1-yl)ethyl!-4-(2,3-dihydro-5-methoxybenzofuran-6-yl)piperazine, or its fumarate.   
     
     
       3. A compound according to claim 1 which is: 4-(2,3-dihydrobenzo-1,4-dioxin-6-yl)-1-(indan-2-ylmethyl)piperazine, or its dihydrochloride.   
     
     
       4. A compound according to claim 1 which is: 1-(indan-2-ylmethyl)-4-(2,3-dihydro-5-methoxybenzofuran-6-yl)piperazine, or its hydrochloride.   
     
     
       5. A method for treating a living animal body afflicted with a condition associated with a dysfunction of the dopaminergic system, comprising the step of administering to the living animal body an amount of a compound of claim 1 which is effective for alleviation of said condition. 
     
     
       6. A pharmaceutical composition acting as D4 receptor ligand and useful in the method of comprising as active ingredient at least one of the compounds according to claim 1, together with one or more pharmaceutical excipients.